Stoke Therapeutics, Inc. (STOK)

NMS – Цена в реальном времени. Валюта: USD

32.97

+0.01 (0.03%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

32.97

0.00 (0.00%)

После закрытия: Aug 12, 2026, 5:26 PM EDT

05.08.2026

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Stoke Therapeutics remains a "Buy," driven by progress on zorevunersen for SCN1A Dravet Syndrome and robust clinical milestones ahead. The company expects an FDA meeting in H2 2026, rolling NDA submission in Q1 2027, and phase 3 EMPEROR data in Q3 2027 for zorevunersen. The advancement of STK-002 for autosomal dominant optic atrophy in the phase 1 OSPREY study showcases the TANGO platform's broader therapeutic potential.

05.08.2026

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Ann.

04.08.2026

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics Inc (NASDAQ:STOK) on Monday posted mixed results for the second quarter.

04.08.2026

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

03.08.2026

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.4 per share a year ago.

03.08.2026

Stoke Therapeutics Q2 Earnings Call Highlights

Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion of enrollment ahead of the company's planned rolling new drug application submission.

03.08.2026

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the second quarter ended June 30, 2026, and provided business updates including progress of the global Pha.

Видео

No Data

There is no data to display

Пресс-релизы

03.08.2026

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the second quarter ended June 30, 2026, and provided business updates including progress of the global Pha.

Stoke Therapeutics, Inc. (STOK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Stoke Therapeutics, Inc. (STOK)

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Q2 Earnings Call Highlights

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Q2 Earnings Call Highlights

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Search stocks

Stoke Therapeutics, Inc. (STOK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Stoke Therapeutics, Inc. (STOK)

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Q2 Earnings Call Highlights

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Q2 Earnings Call Highlights

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates